The Holon-based company, which utilizes its Unigen AI/ML platform to identify novel drug targets, aims to provide updates on its key therapeutic candidates. Central to the discussion are COM701, an anti-PVRIG antibody currently under evaluation in the MAIA-ovarian trial, and rilvegostomig, a PD-1/TIGIT bispecific antibody developed in partnership with AstraZeneca. Additionally, the presentation will cover GS-0321, a high-affinity antibody licensed to Gilead that blocks the interaction between IL-18 binding protein and IL-18.

Interested parties may schedule one-on-one meetings through their BTIG representatives. The company noted that no public replay of the event will be provided following the conclusion of the conference.